Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: A double blind study versus placebo

A. E. Pontiroli, M. Pacchioni, P. M. Piatti, C. Cassisa, R. Camisasca, G. Pozza

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Most obese patients with noninsulin-dependent diabetes mellitus (NIDDM) are initially treated with diet, then with oral hypoglycemic agents, eventually with insulin. However several reports indicate that in these patients insulin therapy has little chance to control glucose metabolism, promotes weight gain and arterial hypertension, and is likely to aggravate insulin resistance. In this randomized, double-blind trial vs. placebo (P) we evaluated in 29 obese NIDDM patients poorly controlled by insulin (daily insulin doses 48.7 ± 4.0 U/day, HbA1c 10 ± 0.27%, mean daily blood glucose levels 12.3 ± 0.3 mmol/L, fasting C-peptide 1.8 ± 0.2, C-peptide after 1 mg iv glucagon 3.2 ± 0.3 ng/mL, means ± SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity. After a 2-3 week run-in period (1 tablet P at dinner and diet 800 cal/day to lose 5% of the initial body weight (BWi), patients received a 1000 kcal/day diet and were randomized to B, 150 mg/tablet, or P (3 tablets/day); the time limit was set at a 10% decrease of BWi or at 90 days. At the end of run-in there was a significant reduction of BWi (P

Original languageEnglish
Pages (from-to)3727-3732
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume81
Issue number10
DOIs
Publication statusPublished - 1996

Fingerprint

benfluorex
Medical problems
Double-Blind Method
Type 2 Diabetes Mellitus
Placebos
Insulin
Tablets
C-Peptide
Body Weight
Nutrition
Diet
Insulin Resistance
Glucagon
Hypoglycemic Agents
Weight Gain
Meals
Blood Glucose
Fasting
Hypertension
Lipids

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin : A double blind study versus placebo. / Pontiroli, A. E.; Pacchioni, M.; Piatti, P. M.; Cassisa, C.; Camisasca, R.; Pozza, G.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 81, No. 10, 1996, p. 3727-3732.

Research output: Contribution to journalArticle

@article{c9612ed2aec94ffc97f20b0d49577d53,
title = "Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: A double blind study versus placebo",
abstract = "Most obese patients with noninsulin-dependent diabetes mellitus (NIDDM) are initially treated with diet, then with oral hypoglycemic agents, eventually with insulin. However several reports indicate that in these patients insulin therapy has little chance to control glucose metabolism, promotes weight gain and arterial hypertension, and is likely to aggravate insulin resistance. In this randomized, double-blind trial vs. placebo (P) we evaluated in 29 obese NIDDM patients poorly controlled by insulin (daily insulin doses 48.7 ± 4.0 U/day, HbA1c 10 ± 0.27{\%}, mean daily blood glucose levels 12.3 ± 0.3 mmol/L, fasting C-peptide 1.8 ± 0.2, C-peptide after 1 mg iv glucagon 3.2 ± 0.3 ng/mL, means ± SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity. After a 2-3 week run-in period (1 tablet P at dinner and diet 800 cal/day to lose 5{\%} of the initial body weight (BWi), patients received a 1000 kcal/day diet and were randomized to B, 150 mg/tablet, or P (3 tablets/day); the time limit was set at a 10{\%} decrease of BWi or at 90 days. At the end of run-in there was a significant reduction of BWi (P",
author = "Pontiroli, {A. E.} and M. Pacchioni and Piatti, {P. M.} and C. Cassisa and R. Camisasca and G. Pozza",
year = "1996",
doi = "10.1210/jc.81.10.3727",
language = "English",
volume = "81",
pages = "3727--3732",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin

T2 - A double blind study versus placebo

AU - Pontiroli, A. E.

AU - Pacchioni, M.

AU - Piatti, P. M.

AU - Cassisa, C.

AU - Camisasca, R.

AU - Pozza, G.

PY - 1996

Y1 - 1996

N2 - Most obese patients with noninsulin-dependent diabetes mellitus (NIDDM) are initially treated with diet, then with oral hypoglycemic agents, eventually with insulin. However several reports indicate that in these patients insulin therapy has little chance to control glucose metabolism, promotes weight gain and arterial hypertension, and is likely to aggravate insulin resistance. In this randomized, double-blind trial vs. placebo (P) we evaluated in 29 obese NIDDM patients poorly controlled by insulin (daily insulin doses 48.7 ± 4.0 U/day, HbA1c 10 ± 0.27%, mean daily blood glucose levels 12.3 ± 0.3 mmol/L, fasting C-peptide 1.8 ± 0.2, C-peptide after 1 mg iv glucagon 3.2 ± 0.3 ng/mL, means ± SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity. After a 2-3 week run-in period (1 tablet P at dinner and diet 800 cal/day to lose 5% of the initial body weight (BWi), patients received a 1000 kcal/day diet and were randomized to B, 150 mg/tablet, or P (3 tablets/day); the time limit was set at a 10% decrease of BWi or at 90 days. At the end of run-in there was a significant reduction of BWi (P

AB - Most obese patients with noninsulin-dependent diabetes mellitus (NIDDM) are initially treated with diet, then with oral hypoglycemic agents, eventually with insulin. However several reports indicate that in these patients insulin therapy has little chance to control glucose metabolism, promotes weight gain and arterial hypertension, and is likely to aggravate insulin resistance. In this randomized, double-blind trial vs. placebo (P) we evaluated in 29 obese NIDDM patients poorly controlled by insulin (daily insulin doses 48.7 ± 4.0 U/day, HbA1c 10 ± 0.27%, mean daily blood glucose levels 12.3 ± 0.3 mmol/L, fasting C-peptide 1.8 ± 0.2, C-peptide after 1 mg iv glucagon 3.2 ± 0.3 ng/mL, means ± SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity. After a 2-3 week run-in period (1 tablet P at dinner and diet 800 cal/day to lose 5% of the initial body weight (BWi), patients received a 1000 kcal/day diet and were randomized to B, 150 mg/tablet, or P (3 tablets/day); the time limit was set at a 10% decrease of BWi or at 90 days. At the end of run-in there was a significant reduction of BWi (P

UR - http://www.scopus.com/inward/record.url?scp=0029798601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029798601&partnerID=8YFLogxK

U2 - 10.1210/jc.81.10.3727

DO - 10.1210/jc.81.10.3727

M3 - Article

C2 - 8855830

AN - SCOPUS:0029798601

VL - 81

SP - 3727

EP - 3732

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -